Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06302374
Other study ID # GR2001-001
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date March 4, 2023
Est. completion date February 19, 2024

Study information

Verified date March 2024
Source Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and Immunogenicity characteristics of GR2001 and compare the anti-tetanus neutralizing antibody titers of GR2001 with human tetanus immunoglobulin (HTIG)in healthy adult subjects.


Description:

This is a Multicentre, Randomized, Double-Blind, Placebo-Controlled, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 Injection in Healthy Subjects. In the phase I part of the study, a total of 94 healthy subjects will be enrolled. The 94 healthy adult subjects will be enrolled into 7 cohorts sequentially. Each participant will receive a single IM dose of GR2001 or placebo or HTIG according to the cohort in which they were enrolled. After injection (Day 0), participants will remain in the study site for observation up to Day 1. The phase I part will last for 105 days following the assessments of safety, PK, PD and ADA. In the phase II part of the study, a total of 108 healthy subjects will be enrolled. The 108 healthy subjects will be randomly assigned to the experimental group and the control group based on a ratio of 1:1:1:2:2:2.The phase II part will last for 105 days following the assessments of safety, PK, PD and ADA.


Recruitment information / eligibility

Status Completed
Enrollment 202
Est. completion date February 19, 2024
Est. primary completion date November 1, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: 1. Healthy male or female, 18-60 years of age (both inclusive); 2. Body mass index within 18.0-27.0 kg/m2 (both inclusive); 3. Subjects including partners are willing to voluntarily take effective contraceptive measures from screening to 6 months after the last study drug administration. 4. Completed written informed consent process, signed the informed consent forms and Agreed to complete all follow-ups. Exclusion Criteria: 1. History or evidence of severe drug or excipient allergy; 2. History or evidence of tetanus infection; 3. Inoculation of tetanus vaccine within 10 years; 4. History or evidence of any other acute or chronic disease; 5. Known or suspected history of drug abuse; 6. Positive outcome for Tetanus-antibody IgG test; 7. Nursing mothers or pregnant women.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
GR2001
intramuscular injection
Placebo
intramuscular injection
HTIG
intramuscular injection
Tetanus Toxoid
intramuscular injection

Locations

Country Name City State
China Huashan Hospital affiliated of Fudan University Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of AEs(Phase I) Number of participants with treatment-related adverse events or serious adverse events. Up to 105 days
Primary Tetanus-antibody titer(Phase II) Tetanus-antibody titer post administration. 24 hours post administration
Secondary Tetanus-antibody titer(Phase I/II) Tetanus-antibody titer post administration. Up to 105 days
Secondary Incidence of ADA(Phase I/II) Incidence of ADA post administration. Up to 105 days
Secondary Incidence of AEs(Phase II) Number of participants with treatment-related adverse events or serious adverse events. Up to 105 days
Secondary Peak plasma concentration(Cmax) Estimated by non-compartmental analysis (NCA) with WinNonlin. Up to 105 days
Secondary Area under the plasma concentration versus time curve (AUC) Estimated by non-compartmental analysis (NCA) with WinNonlin. Up to 105 days
Secondary Time of maximum plasma concentration (Tmax) Estimated by non-compartmental analysis (NCA) with WinNonlin. Up to 105 days
Secondary Terminal half-life (T1/2) Estimated by non-compartmental analysis (NCA) with WinNonlin. Up to 105 days
Secondary Apparent total body clearance (CL/F) Estimated by non-compartmental analysis (NCA) with WinNonlin. Up to 105 days
Secondary Apparent volume of distribution (Vd/F) Estimated by non-compartmental analysis (NCA) with WinNonlin. Up to 105 days
Secondary The elimination rate constant (Kel) Estimated by non-compartmental analysis (NCA) with WinNonlin. Up to 105 days
Secondary Mean Residence Time (MRT) Estimated by non-compartmental analysis (NCA) with WinNonlin. Up to 105 days
See also
  Status Clinical Trial Phase
Completed NCT00352963 - Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age). Phase 3
Not yet recruiting NCT04056728 - A Phase IV Study to Assess the Safety of EupentaTM Inj Phase 4
Completed NCT00753649 - Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants Phase 4
Completed NCT02538211 - The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses N/A
Completed NCT01917357 - A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject Phase 3
Completed NCT01689324 - Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in Adolescents Phase 1/Phase 2
Completed NCT01444781 - Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants Phase 3
Completed NCT01214889 - Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants. Phase 3
Completed NCT00804284 - Database Surveillance Safety Study of PENTACEL® Vaccine N/A
Completed NCT00514709 - Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants Phase 3
Completed NCT00534833 - Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™ Phase 3
Completed NCT00379977 - Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age Phase 3
Completed NCT00772369 - Retrospective Survey of Safety of Fourth Dose Pentacel® in Children Phase 4
Completed NCT00879827 - Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants Phase 3
Completed NCT01457495 - Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly Phase 2
Completed NCT01267058 - Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy Adults Phase 3
Completed NCT02853929 - Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Phase 4
Completed NCT02858440 - A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia Phase 3
Recruiting NCT06049940 - Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old Population Phase 3
Completed NCT00385255 - Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults Phase 3